The effect of the recently cloned cytokine bone morphogenetic protein 9 (BMP-9) on colony formation and generation in vitro clonable hematopoietic progenitors (CFU-C) in serum-free liquid cultures (LC) of both normal and post-5-fluorouracil murine bone marrow cells was studied in the presence of various other cytokines. In LC, BMP-9 concentrations of 100 ng or more per ml led to complete inhibition of Steel Factor (SF) + interleukin-11 (IL-11) or IL-12 supported CFU-C generation, which was partly abrogated when IL-3 was additionally included. We found this inhibitory effect of BMP-9 to be mediated by an increased TGF-␤1 elaboration and TGF-␤1 mRNA expression in bone marrow cells with increasing BMP-9 concentrations. In the presence of neutralizing antibodies (Ab) against TGF-␤1, BMP-9 concentrations of 3 ng or higher synergized with IL-3, SF+IL-3, SF+IL-11/12, or IL-3+SF+IL-11/12 to increase CFU-C generation. Similarly, high BMP-9 concentrations dramatically inhibited primary colony formation induced by SF+IL-11/12, whereas in the presence of TGF-␤1 neutralizing Ab only 3 ng or more BMP-9 per ml stimulated both the time of colony appearance, the colony size and colony numbers in the presence of IL-3, M-CSF, GM-CSF, SF, SF+Flt3-L, SF+IL-3, SF+IL-11/12 or IL-3+SF+IL-11/12. BMP-9 neither stimulated CFU-C generation nor colony formation as a single factor, nor did it synergize with thrombopoietin (Tpo), erythropoietin (Epo), Flt3-L, IL-11, IL-12 or G-CSF. The effect of BMP-9 on its target cells was direct as demonstrated using single-sorted stem cells. These observations demonstrate that BMP-9 plays a dual role in regulating proliferation of primitive hemopoietic progenitor cells. Thus, in addition to its ability to enhance TGF-␤1 elaboration in bone marrow cells, it acts as a potent synergistic activity that is different from SF, Flt3-L, IL-11 or IL-12. BMP-9 mRNA was exclusively detected in the liver of adult mice, whilst no expression was found in stromal cell lines propagated from day-16 fetal liver or neonatal or adult bone marrow.
Introduction
Bone morphogenetic protein-9 is a new member of the transforming growth factor (TGF)-␤ superfamily.
1,2 Individual members of this family function in a diverse array of various embryonic and adult organ systems. [3] [4] [5] [6] [7] The bone morphogenetic proteins (BMPs) are a group of related proteins, many of which are capable of inducing the formation of new cartilage and bone. In bone marrow stroma they induce the osteoblast phenotype and promote osteogenesis, while simultaneously inhibiting other mesodermal differentiation pathways, such as Correspondence: RE Ploemacher, Department of Hematology, Ee1391, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands; Fax: 31 10 436 7601 Received 27 November 1998; accepted 14 December 1998 adipogenesis and myogenesis. 8 In contrast to the disperse expression pattern of individual TGF-␤ family members, BMP-9 expression in the fetus has been described to be restricted to the liver. 1 RhBMP-9 binds to high affinity receptors expressed on primary rat hepatocytes and on the human liver tumor cell line, HepG2, and additionally induces proliferation in these cells. 2 On the basis of these findings it has been proposed that BMP-9 may play a physiological role in stimulating hepatocyte growth. The fact that BMP-9 also stimulates alkaline phosphatase activity in a murine osteoprogenitor cell line, W-20-17, suggests that other tissues may also be physiological targets for BMP-9. 2 A broader role for BMP is also supported by the observation that 125 I-BMP-9 binds to plasma membrane preparations from adult rat kidney, lung, heart, but not cerebrum, intestine, muscle or blood (S Thies, personal communication).
Regulation of quiescence and proliferation in the hemopoietic stem cell compartment probably is a complex interplay between inhibitory and stimulatory activities that may predominantly act locally. Due to the inherent dispersed nature of hemopoiesis in the body there should exist more systemic regulatory signals controlling the rate of hemopoiesis in answer to immediate demands for blood cells. Such controls seem to be fulfilled by a number of cytokines (IL-1, TNF-alfa, TGF-␤, IFN-g) that have (either direct or indirect) pleiotropic activities and are not easily detectable in serum under steady state conditions. Because many members of the TGF-␤ superfamily show pleiotropism, we set out to test the recently characterized members of the BMP group. We made use of a well-calibrated serum-free liquid culture protocol for ex vivo generation of murine hemopoietic progenitor cells and stem cells. This assay has allowed us to detect both potent inhibitory and stimulatory synergistic activities of BMP-9 on hemopoietic progenitor cells.
Materials and methods

Mice
Male and female (C57BLxCBA)F1 (BCBA) mice, 12 weeks old, were bred in the Central Animal Department of the Erasmus University Rotterdam, The Netherlands, and maintained under clean conventional conditions. The microbiological status of the animals was SPF-5. The drinking water was acidified to pH 2.8. In part of the experiments, bone marrow donor mice were injected with 150 mg 5-fluorouracil (Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS) per kg of body weight in a lateral tail vein at day 6 before harvesting the marrow.
Cell preparation
Bone marrow cells (BMC) were prepared by cleaning femora and tibiae from muscles and tendons and gentle crushing in 429 a mortar using PBS+5% fetal bovine serum (FBS). The cell suspensions were sieved over a nylon filter (mesh size 100 m). For buoyant density centrifugation a modification of a discontinuous Ficoll-400 (Pharmacia Fine Chemicals, Uppsala, Sweden) gradient designed to isolate thymocyte and bone marrow subpopulations 9 was used. Cells with a density of 1.069-1.078 g/ml were collected, washed twice in PBS and 5% FBS, and properly diluted. This cell preparation is further designated LD/FU 6d BMC. In some experiments, LD normal BMC and LD/FU 6d BMC were further enriched for hemopoietic progenitor cells by depletion of mature lineage-restricted cells. Briefly, these cells were incubated with mAbs against CD4, CD8,B220, Gr-1, Mac-1 and Ter119 antigens (Pharmingen), followed by goat anti-rat microbeads (Miltenyi) and negative selection on MACS BS columns (Miltenyi, Bergisch Gladbach, Germany). This fraction will be referred to as the LIN− preparation.
Fluorescence activated cell sorting (FACS)
FACS was done essentially as described previously. 9 Briefly, LD/FU 6d BMC cells were incubated with 0.25 g/ml fluorescinated wheat germ agglutinin (WGA-FITC; Vector, Burlingame, CA, USA) prior to sorting using a FACS Vantage (Becton Dickinson, Sunnyvale, CA, USA) with a single argon laser at 488 nm tuned at 350 mW output. FITC intensity were measured using a 510/515 LP and 540 SP filter set. Cells were sorted individually into each well of two microtiter plates per group using a single cell deposition unit. WGA-bright cells represented the highest 25% of all WGA-binding cells and 8% of all LD/FU 6d BMC cells.
Growth factors
Recombinant human BMP-9 was purified from CHO cells as previously described 6 and batches contained 29-492 g/ml. Recombinant human erythropoietin (Epo) was obtained from Merckle (Ulm, Germany). Purified recombinant human thrombopoietin (Tpo) was obtained from Genentech (San Francisco, CA, USA) and its protein concentration was 480 g/ml. Recombinant murine IL-3 was used as conditioned medium from CHO cells containing the appropriate cDNA and its biological activity was determined by stimulation of RB5. Recombinant murine GM-CSF was used as conditioned medium from transfected COS-1 cells and the activity was determined by RB5 assay, while recombinant murine G-CSF was also produced in COS-1 and the biological activity was 16 300 U/ml as determined by RB5 proliferation assay. Recombinant human M-CSF was purified from CHO cells expressing M-CSF cDNA and batches contained 860 g/ml with a biological activity of 1.65 × 10 6 U/ml as determined by 32Dcfms cell proliferation using 3 H-thymidine incorporation. Purified recombinant human IL-11 (produced in E. coli) had a specific activity greater than 1 × 10 6 U/mg as determined by the T10 cell proliferation assay. Purified recombinant human Flt3-L was produced in E. coli and contained 700 g/ml. Soluble recombinant murine c-kit ligand (Steel Factor; SF) was purified from CHO cells to give batches containing 322 g protein/ml. Heterodimeric recombinant murine IL-12 was purified from the conditioned medium of NSO myeloma cells containing an expression vector producing both murine p35 and p40 subunits. The specific activity of the pure material, measured with a human PHA-blast cell assay, was approximately 3 × 10 6 units/mg. BMP-9, IL-3, IL-11, IL-12, GM-CSF and M-CSF were kindly provided by the Genetics Institute (Cambridge, MA, USA), SF and Flt3-L by Amgen (Thousand Oaks, CA, USA). Unless otherwise indicated concentrations of factors were as follows: SF, 50 ng U/ml; Flt3-L, 50 ng/ml; IL-3, 5 ng/ml; IL-11, 50 ng/ml; IL-12, 1 ng/ml; rhG-CSF, 20 ng/ml; M-CSF, 100 ng/ml; GM-CSF, 20 ng/ml; Tpo, 100 ng/ml; Epo, 1 U/ml.
Clonogenic assays
Quantitation of CFU-C was carried out in duplicate to quadruplicate 35-mm bacteriological dishes (627102, Greiner, Alfen aan de Rijn, The Netherlands) in a fully humidified incubator at 37°C and 5% CO 2 . One milliliter of culture contained either 2-10 × 10 3 LD/FU 6d BMC or 5-50 × 10 3 NBMC in semisolid (0.8% methylcellulose; Methocel AP4 Premium, Dow Chemical, Rotterdam, The Netherlands) serum-free culture medium (IMDM with Glutamax-1; Gibco, Breda, The Netherlands, cat No. 31980-022 and penicillin/streptomycin). The medium was complemented with 1 × 10 −4 mol/l 2-mercaptoethanol (Merck, Darmstad, Germany), 1% bovine serum albumin (Sigma), 10 g/ml bovine insulin (Gibco), 15 × 10 −3 m cholesterol (Sigma), 15 × 10 −3 m linolic acid (Merck), 154 g/ml iron-saturated human transferrin (Behring Institute, Marburg, Germany), a nucleoside mix of 1 g/ml of cytidine, adenosine, uridine, guanosine, 2Ј-deoxycytidine, 2Ј-deoxyadenosine, thymidine, 2Ј-deoxyguanosine (all from Sigma) and cytokines as specified per experiment. Colonies (у50 cells) and clusters (8-49 cells) were counted on various time points between day 5 and 21 of culture with an inverted microscope. In some experiments colonies were plucked individually from the cultures on day 14, May-Grü nwald-Giemsa stained and the presence of specific lineages (either monocyte, macrophage, neutrophil, eosinophil, erythroid, megakaryocytic, blast cell or mast cell) per colony was determined. For quantitation of liquid culture CFU-C output the CFU-C culture medium included 20% horse serum, while 10% of pokeweed mitogen-stimulated mouse spleen-conditioned medium (PWM-MSCM) was used as growth stimulus. Colonies in all cultures were counted at day 7 and 14 of culture with an inverted microscope.
Liquid culture
Serum-free liquid suspension cultures were performed in 1-ml volumes in 35-mm bacteriologic dishes (627102, Greiner) with one to four dishes per group according to the anticipated cell number required for replating in the CFU-C assays. The medium was similar to that used for serum-free primary colony assays. The cells were incubated for 5-7 days at 37°C and 10% CO 2 in a fully humidified incubator. At the end of the incubation period cells were replated in the CFU-C assay with 20% horse serum and 10% pokeweed mitogen-stimulated mouse spleen cell conditioned medium (PWM-MSCM) as colony-stimulating activity.
HepG2 assay
The human liver tumor cell line, HepG2 (ATCC HB8065) was obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were plated at 10 5 cells in 200 l in 96-well plates and cultured for 44 h in IMDM/0.1% FCS with or without 10 or 300 ng rhBMP-9/ml, 0.3 or 10 ng TGF-␤1/ml or 1 g of anti-TGF-␤1 antibodies/ml.
3 H-thymidine was included in the last 20 h of the incubation period and cellular DNA was harvested with a 96-well plate cell harvester. Incorporated 3 H-thymidine was measured by liquid scintillation counting.
BMP-9 binding
For binding experiments, suspension of spleen, thymus, normal BMC (NBMC), FU 6d BMC or lineage-depleted (Lin−) fractions of NBMC or FU 6d BMC were centrifuged on gelatinized glass slides. The cells were incubated with 1 ng/ml 125 I-BMP-9 with or without 100 ng/ml of unlabeled rhBMP-9 in binding buffer (50 mm Tris, 100 mm NaCl, 5 mm CaCl 2 , 3% BSA, 0.1 mm bacitracin, 0.15 m aprotinin, 1 mm pefabloc, 8 mm leupeptin, pH 7.4) for 2 h at 25°C following a 30 min preincubation at 37°C in binding buffer alone. Cells were washed three times in ice-cold binding buffer, fixed in 0.5% glutaraldehyde in binding buffer and dried in cool air. The dried slides were coated with Ilford K.5 emulsion, exposed for 3 weeks and stained with toluidine blue. RhBMP-9 was iodinated to a specific activity of 50-100 Ci/g by the methods of Frolik et al. 10 Iodinated rhBMP-9 and unlabeled rhBMP-9 exhibited similar potencies on HepG2 cell proliferation. 2 
RNA assay
For TGF-␤1 mRNA expression, 10 5 LD/FU 6d BMC were cultured for 4 days in 33 mm-diameter bacterial petri dishes containing serum-free medium with 50 ng SF, 1 ng IL-12 with or without 100 ng BMP-9 and 1 g anti-TGF-␤1 antibody per ml. FBMD-1 stromal cells were cultured to confluency, the 10% horse serum containing medium changed for the same medium as used for the LD/FU 6d BMC, and the cells were harvested by trypsinization after 4 days. For BMP-9 mRNA expression, total RNA was prepared from adult mouse liver, spleen, bone marrow, lymph nodes, thymus, and from bone marrow derived (FBMD-1, NBM-11F4G, NB-11F10H, NBM-6D3D) or fetal liver-derived (FL-7H7B and FL-1E2C) stromal cells.
Total cellular RNA was isolated from tissues or cell suspensions by extraction with TRIzol Reagent (Gibco, cat No. 15596-026). cDNA synthesis 11 was performed starting with 1-3 g RNA, after heating for 10 min at 65°C. Semi-quantitative PCR was performed on 3-5 cDNA batches prepared from different experiments using a 100 l mixture containing 1/20 of the cDNA products (in 50 l). TAq polymerase buffer (100 mm Tris-HCl, 500 mm KCl, 15 mm MgCl 2 and 1% gelatin; pH 8.3), 0.2 mm of each dNTP (Pharmacia) and 1 unit of Taq polymerase (Promega). In addition, 50 pmol of the following sense and anti-sense primers were added: HPRT, 5Ј-GTA ATG ATC AGT CAA CGG GGG AC and 3Ј-CCA GCA AGC TTG CAA CCT TAA CCA, product size 179 bp; TGF-␤1, 5Ј-GAC GTC AAA AGA CAG CCA CT, 3Ј-GAA GCC ATC CGT GGC CAG AT, product size 461; BMP-9,5Ј-GAAGGTGGAT TT CCTACGCA, 3Ј-CACTGTCACC TCGAGCTTAT, product size 504 bp. After 15, 20, 25, or 30 cycles for TGF-␤1, or 45 cycles for BMP-9, 10 l of the PCR product was removed from the reaction tube, samples were submitted to electrophoresis in a 2% agarose gel and differences between groups were determined by comparing the number of cycles required to get a similar electrophoretic density. The level of cellular mRNA expression was monitored by using primers for HPRT as a housekeeping gene.
Results
BMP-9 inhibits CFU-C generation in LC
Among a series of BMPs that we tested in the 10-50 ng ranges on their ability to affect maintenance and generation of progenitors and stem cells in liquid cultures (LC), rhBMP-9 was inhibitory. To determine a dose response for the inhibitory effect of BMP-9 we performed 5-day serum-free LC of 2 × 10 4 LD/FU 6d BMC stimulated by either SF+IL-12, or SF+IL-12+IL-3 (5 U/ml). Previously we have found these cytokine combinations to synergize in progenitor cell generation and colony formation of murine bone marrow cells, 12, 13 and to be extremely useful for detecting the presence of very low concentrations of TGF-␤1 (ie down to 1 pg/ml).
14,15 From Figure  1 it appears that BMP-9 concentrations of 100 ng and higher, completely abrogated CFU-C generation stimulated by SF+IL-12, and almost completely when low concentrations of IL-3 (5 U) were included. The same effect could be observed if IL-12 was replaced by IL-11 (data not shown). These observations indicate that BMP-9 can act as a potent inhibitory activity for CFU-C generation. Similarly, 100 ng BMP-9 completely inhibited colony formation by LD/FU 6d BMC in the presence of SF+IL-12 (data not included in Tables or Figures) .
IL-3 partly abrogates the inhibition of CFU-C generation by BMP-9 in LC
We further investigated whether IL-3 was indeed able to abrogate the inhibition by BMP-9 as it does with TGF-␤1. 15 From Figure 2 it can be seen that increasing IL-3 concentrations in SF+IL-12 containing cultures did not induce a significant increased CFU-C generation in 5-day LCs, however, clearly abrogated part of the 100 ng BMP-9 mediated inhibition of CFU-C production. In view of our previous observations 14, 15 that IL-3 partly abrogates the TGF-␤1-induced inhibition of colony formation and CFU-C generation in the presence of
Figure 1
Dose-response of rhBMP-9 in 5-day serum-free liquid cultures of 2 × 10 4 LD/FU 6d BMC/ml. Input cells contained 360 day-8 CFU-C, while output was 19 250 when SF (50 ng/ml) + IL-12 (1 ng/ml) was used as stimulus, and 46 500 when SF+IL-12+IL-3 (5 U/ml) was included. The data represent the arithmetic mean of duplicate dishes in a representative experiment.
Figure 2
Dose-response of IL-3 in 5-day serum-free liquid cultures of 2 × 10 4 LD/FU 6d BMC/ml. Input cells contained 370 day-8 CFU-C, while output was 19 500 CFU-C day-7 when SF+IL-12 was used as stimulus, and 23 000 when SF+IL-12+IL-3 (100 U/ml) was included. BMP-9 was added at 100 ng/ml. The data represent the arithmetic mean of quaduplicate dishes in a representative experiment.
SF+IL-12, the present data suggested to us that either TGF-␤1 mediates the inhibition of BMP-9, or that TGF-␤1 and BMP-9 could have identical effects in that respect.
TGF-␤1 mediates the inhibition of CFU-C generation by BMP-9 in LC
To study this possibility, we performed similar 5-day LC with 2 × 10 4 LD/FU 6d BMC per 1 ml culture stimulated by SF+IL-12, with or without IL-3, and added neutralizing concentrations of antibodies (Ab) against TGF-␤1. Table 1 shows that not only could 1 g of anti-TGF-␤1 Ab prevent the inhibition by 100 ng of BMP-9, but it led to a further increased CFU-C generation both when SF+IL-12, or SF+IL-12+IL-3 were included. Antibodies against IFN-gamma did not have any effects (data not shown). These data strongly suggested that BMP-9 not only induces or enhances TGF-␤1 elaboration by the cultured BMC, but in addition may stimulate CFU-C generation driven by SF+IL-12 with or without IL-3.
To investigate the fate of progenitor cells in BMP-9-contain- ing cultures during the course of the culture we performed 7-day cultures of 2 × 10 4 LD/FU 6d BMC in the presence of SF+IL-12+BMP-9 (100 ng) and added anti-TGF-␤1 Ab either on day 0, 2 or 4. Cultures were replated at 4 h, and on days 1, 2, 3, 4 and 7 for estimation of the CFU-C number recovered. On a per 10 5 input cell basis about 2500 CFU-C were inoculated at day 0, and 6 × 10 5 CFU-C were generated in 7 days when only SF+IL-12 was present (Figure 3) . The more delayed the anti-TGF-␤1 Ab was added to the culture, the less CFU-C were finally retrieved on subsequent days, including day 7. However, in the absence of anti-TGF-␤1 Ab, CFU-C could always be detected, although at lower numbers than when started. These data show that the progenitors generating the CFU-C were not immediately killed by BMP-9, or by the induced TGF-␤1, and that upon neutralization of TGF-␤1 growth curves ensued in a manner roughly parallel to the SF+IL-12 ('none' in Figure 3 ) stimulated cultures. Remarkably, the CFU-C growth curve in the group that contained BMP-9 and anti-TGF-␤1 Ab for the whole culture period started earlier than in the SF+IL-12 group and after day 2-3 parallelled the other growth curves at a higher level. This indicates that
Figure 3
Effect of delayed addition of anti-TGF-␤1 antibody (Ab) (1 g/ml) to liquid cultures of 2 × 10 4 LD/FU 6d BMC/ml containing SF (50 ng/ml) + IL-12 (1 ng/ml) + BMP-9 (100 ng/ml). BMP-9 was present during the whole culture period, while Ab was added to the cultures at the beginning of the culture period (Ab), or at day 2 [(2d)Ab] or day 4 [(2d)Ab]. The data represent the arithmetic mean of quaduplicate dishes in a representative experiment. BMP-9 initiates early proliferation in hemopoietic progenitor cells in the presence of SF+IL-12, rather then stimulating CFU-C expansion over the whole culture period. Our data also suggest that BMP-9 activates additional progenitors that had otherwise remained quiescent.
The observation that BMP-9 could increase CFU-C generation by SF+IL-12 with or without IL-3 (see Table 1 ) in the presence of anti-TGF-␤1 Ab also shows that the antibody did not neutralize the BMP-9. To obtain additional evidence for this notion we tested whether BMP-9 in the presence of the Ab could still stimulate proliferation of BMP-9 sensitive HepG2 cells, which it could. TGF-␤1 significantly inhibited their growth as measured by 3 H-thymidine uptake (Figure 4 ).
BMP-9 increases steady state TGF-␤1 mRNA levels in LD/FU 6d BMC
To confirm the ability of BMP-9 to induce TGF-␤1 in cultures of bone marrow cells, we cultured either LD/FU 6d BMC at 2 × 10 4 ml, or confluent FBMD-1 stromal cells, for 4 days in dishes in the presence of SF+IL-12 and anti-TGF-␤1 Ab, with or without 100 ng of BMP-9/ml. Total RNA was extracted on day 4 and RT-PCR performed with intermittent sampling between cycles. Figure 5 shows that at 25-30 PCR cycles a visible TGF-␤1 band was present in the LD/FU 6d BMC exposed to BMP-9, whereas without BMP-9 no TGF-␤1 signal was observed. As stromal cells are well known producers of TGF-␤1, we tested whether BMP-9-induced TGF-␤1 mRNA over-expression also occurred in the stromal cell line FBMD-1, which it did not. Therefore, these data suggest that the BMC themselves have BMP-9 receptors and that BMP-9 stimulation either upregulates TGF-␤1 mRNA, or stabilizes TGF-␤1 message, which may lead to an increased elaboration of TGF-␤1. The data also point to the possibility that the TGF-␤1-mediated inhibitory action of BMP-9 may not involve the bone marrow stroma.
Figure 4
Anti-TGF-␤1 antibody (Ab) does not abrogate the BMP-9-induced proliferation of HepG2 cells. HepG2 cells (10 5 /ml) were plated in 100 l in 96-well plates and cultured for 44 h with or without rhBMP-9, TGF-␤1 or anti-TGF-␤1 antibodies.
3 H-thymidine was included in the last 24 h of the incubation period. The data represent the arithmetic mean of triplicate wells in two separate experiments as a percentage of cultures without Ab or cytokine addition (none). 
BMP-9 is a potent stimulator of CFU-C generation
Because the stimulatory ability of BMP-9 could occur in a different dose range than its inhibitory action, a BMP-9 dose response was investigated under conditions where the BMP-9-induced TGF-␤1 production is efficiently neutralized. To this end we performed 6-day LC of 2 × 10 4 LD/FU 6d BMC in the presence of SF+IL-12 and either added 4, 1 or 0.1 g of anti-TGF-␤1 Ab to these LC. In the presence of 1 or 4 g anti-TGF-␤1 Ab increasing BMP-9 concentrations led to an increased CFU-C generation with a plateau reached at only 3-30 ng BMP-9/ml ( Figure 6 ). At higher BMP-9 concen-
Figure 6
Dose-response of the stimulatory effect of BMP-9 on CFU-C generation in 5-day liquid cultures of 2 × 10 4 LD/FU 6d BMC/ml containing anti-TGF-␤1 antibody (Ab). All cultures were stimulated with SF (50 ng/ml) + IL-12 (1 ng/ml). Input cells contained 2025 CFU-C day-14/10 5 nc. Data represent arithmetic means (error bars, 1 s.d.) of quadruplicate dishes in a representative experiment. Pilot experiments where part of these factors were tested yielded similar results.
trations, less CFU-C were generated, probably as a result of increasing TGF-␤1 elaboration, which could not be completely neutralized by this dose of Ab. In the presence of only 0.1 g of anti-TGF-␤1 Ab the BMP-9 dose response was similar, albeit that at 3-300 ng of BMP-9 even less CFU-C were generated. These data show that BMP-9 proper stimulates CFU-C generation in the presence of SF+IL-12. In addition, our findings strongly suggest that the BMP-9 evoked TGF-␤1 elaboration increases when BMP-9 concentrations are increased.
BMP-9 synergizes with various (combinations of) cytokines to increase progenitor generation
Next we investigated the mechanism of the BMP-9 stimulation of CFU-C generation, ie whether BMP-9 had growth stimulating activity as a single factor, and/or displayed synergistic activity. To this end LC of 2 × 10 4 LD/FU 6d BMC were set up and either an array of single growth factors or some potent cytokine combinations were included with or without 10 ng of BMP-9 and always in the presence of neutralizing concentrations of anti-TGF␤1 Ab (1 g/ml). The results of these experiments have been summarized in Table 2 . In the presence of BMP-9 alone, no CFU-C were recovered from the LC. Few or no CFU-C were generated in cultures containing IL-11, IL-12, G-CSF, GM-CSF, SF, Flt3-L, Tpo or IL-3 as single factors. BMP-9 synergized only with IL-3. In multicytokinecontaining cultures BMP-9 showed potent synergy with all combinations that contained either SF+IL-3, SF+IL-11 or SF+IL-12. BMP-9 could not increase CFU-C generation stimulated with potent cytokine combinations, ie IL-3+SF+IL-12 with or without Flt3-L+Tpo possibly because these factor con- Table 2 Synergistic effects of BMP-9 on CFU-C generation in 6-day liquid cultures of LD/FU 6d BMC in the presence of neutralizing anti-TGF-␤1 antibodies
Cytokines
Mean number of CFU-C (1 sd) generated per 10 5 input nucleated cells 2 × 10 4 LD/FU 6d BMC were cultured in 1 ml serum-free LC in the presence of cytokines and 10 ng BMP-9/ml. All cytokine-containing groups contained antiTGF-␤1 antibodies. a The mean of the fold increase with BMP-9 as determined in individual experiments. b Input and output CFU-C cultures included 10% PWM-MSCM as a growth stimulus. c 100 U IL-3/ml. ditions already maximally stimulated progenitor growth. Indeed, in all these cultures 100% of the output cells were demonstrated to be clonogenic. Because all of these cytokines were used at plateau concentrations, these data suggest that the synergy of BMP-9 is different from that of SF, IL-11 or IL-12.
BMP-9 synergizes with various (combinations of) cytokines to increase primary colony formation
As shown in Table 2 LD/FU 6d BMC show a low or absent responsiveness to single cytokine stimulation. In order to get a better insight of possible synergies of BMP-9 with single factors we studied primary colony formation using normal BMC and only included LD/FU 6d BMC to study particular multicytokine combinations. As expected, single factors stimulated less colony formation then did multiple factor combinations ( Table  3 ). In NBMC, BMP-9 did not stimulate any colony formation as a single factor, but significantly synergized to increase colony formation by SF, GM-CSF, M-CSF, IL-3, SF+Flt3-L, SF+IL-11, SF+IL-12, SF+IL-3, SF+IL-11+IL-3 or SF+IL-12+IL-3. As far as we have determined, this was also observed in LD/FU 6d BMC. In all of these cultures BMP-9 accelerated colony development, which was particularly evident in the first 5 days of culture. No synergy of BMP-9 was seen in combination with IL-11, IL-12, G-CSF, Flt3-L, Tpo, Flt3-L+IL-12, or SF+Epo+Tpo. Some of these observations could have been due to the (virtual) lack of colony formation that prohibited analysis of synergistic effect, eg with IL-11, Il-12, Flt3-L and Tpo. However, in two out of three combinations that included Flt3-L (ie with either SF, IL-12 or IL-3) BMP-9 did not synergize, suggesting that BMP-9 and Flt3-L could act via similar or over- Table 3 Synergistic effects of BMP-9 on primary colony formation by normal bone marrow cells and LD/FU 6d BMC in the presence of neutralizing anti-TGF-␤1 antibodies
Cytokines
Number Haemin was included. Red and white colonies were separately scored. d BMP-9 was included at 10 ng/ml. lapping mechanisms. Similarly, BMP-9 and Tpo may show overlapping activities. As all cytokines were used at plateau concentrations, we conclude that the synergistic activity of BMP-9 is different from that of SF, IL-11 or IL-12. The differential analyses of plucked colonies from cultures that included SF+IL-11, SF+IL-12, SF+IL-3, SF+IL-11+IL-3 or SF+IL-12+IL-3 with or without BMP-9 did not reveal any effect of BMP-9 on lineage differentiation in such colonies (data not shown).
BMP-9 acts directly on hemopoietic progenitor cells
In order to investigate if BMP acted on the colony-forming cells proper, or via assessory cells, we sorted LD/FU 6d BMC on the basis of WGA high affinity in a scatter blast cell window as previously described. 9, 16 This cell population is almost homogenous for day-12 spleen colony-forming units in the spleen (CFU-S-12), that we have previously shown to represent predominantly transient repopulating stem cells in vivo. 9, 16 In cultures containing SF+IL-11, SF+IL-3 or SF+IL-3+IL-11, single plated cells in individual wells of microtiter plates formed 51-112% more clones in the presence of 10 ng/ml BMP-9 as without ( Table 4 ), demonstrating that BMP-9 acted directly on these cells. BMP-9 did not stimulate cluster or colony formation as a single agent in these cultures. Data represent the compiled data of two separate experiments. a BMP-9 was included at 10 ng/ml. All cultures contained anti-TGF-␤1 Ab at 1 g/ml.
BMP-9 receptors are expressed on hemopoietic cells
As all the previous data extensively indicated that at least some BMC have BMP-9 receptors, we performed 125 I-BMP binding in order to quantitate the percentage of cells expressing BMP-9 receptors. Cells were centrifuged on glass slides and incubated with 1 ng/ml 125 I-BMP-9 with or without excess cold BMP-9 and processed as detailed in Materials and methods. Following exposure cells were stained with toluidine 435 blue. In normal BMC specific and abundant 125 I-BMP-9 labelling was observed on megakaryocytes and small blast cells. About 10% of neutrophils and immature myeloid cells also showed 125 I-BMP-9 binding which could, however, not be competed away with cold BMP-9, strongly suggesting that binding to these cells was nonspecific. Both in spleen and thymus preparations lymphocytes showed weak but specific 125 I-BMP-9 binding that could be completely blocked by excess cold BMP-9. Interestingly, in a LIN− preparation of FU 6d BMC the majority of cells, mainly consisting of small blasts, were specifically and abundantly labelled with 125 I-BMP-9 ( Figure 7) . The small blast cells are likely to include many CFU-C and more primitive stem cells as few lymphocytes and erythroblasts are present in the LINϪ preparations. These observations indicate that BMP-9 receptors are highly expressed on immature bone marrow cells and on megakaryocytes.
BMP-9 mRNA is expressed in the liver
Using 45 cycles of RT-PCR, BMP-9 mRNA expression was exclusively observed in the liver, but not in spleen, bone mar- row, lymph nodes or thymus. BMP-9 mRNA could also not be detected in a series of fetal liver-derived and bone marrowderived stromal cell lines (data not shown).
Discussion
The present data demonstrate that rhBMP-9 is both a stimulator of TGF-␤1 transcription and elaboration in bone marrow cells and a potent synergistic activity for primary colony formation and progenitor cell generation in vitro. Because BMP-9 excerts its effect in combination with saturating concentrations of SF, M-CSF, GM-CSF, IL-3, IL-11 and IL-12 its synergism is probably different from that of these cytokines. This suggests that BMP-9 acts via a novel mechanism rather than by induction of endogenous production of the above-mentioned cytokines or by up-regulation of their receptors. As discussed in Results, however, there is a theoretical possibility that BMP-9 synergizes through mechanisms that overlap with those of Tpo and/or Flt3-L. BMP-9 is a genuine synergistic factor for hemopoietic cells because it did not show activity as a single factor. It displays characteristics of competence factors that may both release progenitors from cell cycle quiescence that would either not have been activated or had required more time to do so.
17, 18 The proliferation of eurkaryotic cells is tightly regulated through a delicate balance of positive and negative regulatory proteins that exert their effects during the first gap phase (G 1 ) of the cell cycle. 19, 20 Inhibition of cell growth by TGF-␤ occurs in mid G 1 , largely through its ability to down-regulate the activity of the cyclindependent kinases cdk2 and cdk4. 21 Our present demonstration, that BMP-9 is able to induce TGF-␤1 mRNA and increase TGF-␤1 elaboration by bone marrow cells, is a novel finding. This observation is reminiscent of the increased TGF-␤1 expression in a human osteoblast cell line by BMP-2 22 and in human monocytes by BMP-4. 23 Because we did not find increased TGF-␤1 mRNA levels in a series of stromal cells stimulated with BMP-9, our data suggest that BMP-9 does not act on bone marrow stroma. However, a more definitive conclusion requires the determination of TGF-␤1 mRNA levels in primary stromal cells exposed to BMP-9.
We have shown that the synergistic activities of rhBMP-9 are optimal at only 3 ng, which indicates that BMP-9 is an extremely potent cytokine, as is for example IL-12. Our data indicate that the physiological role of BMP-9 is complex and possibly being realised by subtle changes in its concentration. Thus, the stimulatory activities of BMP-9 are displayed at low concentrations whereas increasingly more TGF-␤1 is induced by increasing levels of BMP-9. In vivo the elaborated TGF-␤1 may not be as inhibitory as in our LC in bacterial dishes that do not inactivate TGF-␤1. It is conceivable that TGF-␤1, elaborated in the stromal microenvironment, is neutralized by a variety of mechanisms including TGF binding proteins. 24 Cells may secrete small latent TGF-␤1 as a disulfide-bonded complex with a member of the latent TGF-␤1 binding protein (LTBP) family. These LTBPs may act locally as autocrine or paracrine regulators of TGF-␤1 activity in specific tissues and play an important role for the interaction of the latent TGF-␤1 complex with extracellular matrix components. 25 It has to be investigated whether BMP-9 may be less inhibitory to longterm stroma-supported cultures than in LC.
Our data show that the presence of BMP-9 during a 7-day liquid culture period induced only moderate loss of input CFU-C. The neutralization of TGF-␤1 on day 2 or 4 led to a delayed onset of CFU-C production with a growth rate largely similar to that of cultures wherein TGF-␤1 had been neutralized as of day 0 (see Figure 3 ). This suggests that the responsive cells had been quiescent in the presence of active TGF-␤1. In the presence of anti-TGF-␤1 Ab, BMP-9 affected the CFU-C growth curves only in the first 2-3 days of culture, indicating that it activated quiescent CFU-C precursor cells to start proliferation rather than stimulating CFU-C generation during the full culture period.
The possibility that the neutralizing Ab against TGF-␤1 would bind to BMP-9 and so abrogate the inhibitory effects of BMP-9 can be refuted. In the presence of the Ab, BMP-9 exerted stimulatory effects on CFU-C generation and colony formation of hemopoietic progenitors, and in addition stimulated HepG2 cells. Furthermore, if the amount of neutralizing Ab is calculated on the basis that TGF-␤1 has a much higher potency (100-300 pg completely inhibits CFU-C generation and colony formation) 14, 15 compared to BMP-9 (full inhibition at 100-300 ng), it would theoretically require at least 1 mg/ml of Ab to neutralize the BMP-9 if it cross-reacts at all.
We found BMP-9 to be exclusively expressed in the adult mouse liver, but not in fetal liver-derived stromal cell lines, suggesting that BMP-9 may be produced by hepatocytes. In contrast to growth factors and cytokines as TGF-␤1, PDGF, IGF-I, IGF-II, and FGF that have effects on many other tissue and cell types, the bone morphogenetic proteins (BMPs) have been suggested to represent a unique set of differentiation factors that induce new bone formation at the site of implantation instead of changing the growth rate of pre-existing bone. 26 BMP-9 has been suggested to play a physiological role in hepatocyte proliferation and possibly in osteogenic differentiation. 2 The binding of 125 I-BMP-9 to membrane preparations of rat kidney, lung and heart (S Thies, personal communication) and our present finding of BMP-9 binding to bone marrow cells, suggests that BMP-9 may have physiological roles unrelated to bone formation. Cross-linking analysis has indicated that human HepG2 liver tumor cells bind recombinant human BMP-9 (rhBMP-9) with high affinity. Up to now, the BMP-family members have not been suggested to play a role in regulation of hemopoiesis, but a single member may rather effect hemopoietic ontogeny. Thus, it has been demonstrated recently that BMP-4 is a potent centralizing factor and inducer of hematopoietic tissue while repressing dorsal mesoderm formation in Xenopus embryos. BMP-4 can also stimulate GATA-2 expression in ventral mesoderm leading to increased globin production. [27] [28] [29] More characteristic of most BMP members, however, is that they regulate morphogenetic processes, including but not limited to, skeletal development. As an example, BMP-7 may also be required for nephrogenesis and eye lens development 30 while BMP-6 has been suggested to be neuron-specific and to play an important role in neuronal maturation and synapse formation. 31 Finally, because of its hepatic action and ability to induce TGF-␤1, BMP-9 is not a likely candidate cytokine to be systemically applied following cytoreductive therapy. However, because the TGF-␤1 production by BMC can be effectively blocked in vitro, BMP-9 seems an interesting novel activity for ex vivo propagation and expansion of hemopoietic progenitors and possibly stem cells.
